Multiple immune-cell types can infiltrate tumors and promote progression and metastasis through different mechanisms, including immunosuppression. How distinct genetic alterations in tumors affect the composition of the immune landscape is currently unclear. Here, we characterized the immune-cell composition of prostate cancers driven by the loss of the critical tumor suppressor gene Pten, either alone or in combination with the loss of Trp53, Zbtb7a or PML. We observed a striking quantitative and qualitative heterogeneity that was directly dependent on the specific genetic events in the tumor and ranged from 'cold', noninflamed tumors to massively infiltrated landscapes-results with important therapeutic implications. Further, we showed these qualitative differences in transcriptomic analysis of human prostate cancer samples. These data suggest that patient stratification on the basis of integrated genotypic-immunophenotypic analyses may be necessary for successful clinical trials and tailored precision immunological therapies.

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms

Pandolfi P. P.
Last
2018-01-01

Abstract

Multiple immune-cell types can infiltrate tumors and promote progression and metastasis through different mechanisms, including immunosuppression. How distinct genetic alterations in tumors affect the composition of the immune landscape is currently unclear. Here, we characterized the immune-cell composition of prostate cancers driven by the loss of the critical tumor suppressor gene Pten, either alone or in combination with the loss of Trp53, Zbtb7a or PML. We observed a striking quantitative and qualitative heterogeneity that was directly dependent on the specific genetic events in the tumor and ranged from 'cold', noninflamed tumors to massively infiltrated landscapes-results with important therapeutic implications. Further, we showed these qualitative differences in transcriptomic analysis of human prostate cancer samples. These data suggest that patient stratification on the basis of integrated genotypic-immunophenotypic analyses may be necessary for successful clinical trials and tailored precision immunological therapies.
2018
24
2
165
175
http://www.nature.com/nm/index.html
Animals; B-Lymphocytes; DNA-Binding Proteins; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Genotype; Humans; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Mice; Mice, Knockout; Myeloid Cells; PTEN Phosphohydrolase; Promyelocytic Leukemia Protein; Prostatic Neoplasms; T-Lymphocytes; Transcription Factors; Transcriptome; Tumor Suppressor Protein p53
Bezzi M.; Seitzer N.; Ishikawa T.; Reschke M.; Chen M.; Wang G.; Mitchell C.; Ng C.; Katon J.; Lunardi A.; Signoretti S.; Clohessy J.G.; Zhang J.; Pandolfi P.P.
File in questo prodotto:
File Dimensione Formato  
pubb 2.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 2.5 MB
Formato Adobe PDF
2.5 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1732881
Citazioni
  • ???jsp.display-item.citation.pmc??? 86
  • Scopus 122
  • ???jsp.display-item.citation.isi??? 114
social impact